Comparative Pharmacology
Head-to-head clinical analysis: NIPRIDE versus THEROXIDIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NIPRIDE versus THEROXIDIL.
NIPRIDE vs THEROXIDIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nipride (sodium nitroprusside) is a potent vasodilator that acts directly on vascular smooth muscle, both arterial and venous, by releasing nitric oxide (NO). Nitric oxide activates guanylate cyclase, increasing cyclic GMP levels, leading to relaxation of smooth muscle and subsequent reduction in peripheral vascular resistance and blood pressure.
Theroxidil is a vasodilator that acts by opening potassium channels in vascular smooth muscle, leading to hyperpolarization and relaxation. It also inhibits platelet aggregation and reduces peripheral vascular resistance.
Intravenous infusion: initial 0.3-0.5 mcg/kg/min, titrate up to 10 mcg/kg/min as needed.
5 mg orally once daily, increased to 10 mg after 4 weeks as tolerated.
None Documented
None Documented
Nitroprusside: ~2 minutes (converted to cyanide); cyanide (as thiocyanate): 2.7 days; clinical context: continuous IV infusion required; thiocyanate accumulation risk in renal impairment.
Terminal elimination half-life 24-30 hours; steady-state reached after 4-5 days; clinically significant for once-daily dosing
Renal: ~50% as unchanged drug; hepatic metabolism to thiocyanate, which is renally eliminated (half-life 2-3 days); <1% fecal.
Approximately 60% renal (15% unchanged, 45% as glucuronide metabolites), 40% fecal/biliary as metabolites
Category C
Category C
Vasodilator
Vasodilator